These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 31849640)

  • 1. Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management.
    Zhou YW; Zhu YJ; Wang MN; Xie Y; Chen CY; Zhang T; Xia F; Ding ZY; Liu JY
    Front Pharmacol; 2019; 10():1350. PubMed ID: 31849640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.
    Zhou YW; Xu Q; Wang Y; Xia RL; Liu JY; Ma XL
    Int J Ophthalmol; 2022; 15(4):646-656. PubMed ID: 35450191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
    Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
    Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug therapy for myocarditis induced by immune checkpoint inhibitors.
    Wu Y; Xu Y; Xu L
    Front Pharmacol; 2023; 14():1161243. PubMed ID: 37305530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology.
    He Y; Yu H; Dai S; He M; Ma L; Xu Z; Luo F; Wang L
    Genes Dis; 2024 Mar; 11(2):807-818. PubMed ID: 37692505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.
    Ronen D; Bsoul A; Lotem M; Abedat S; Yarkoni M; Amir O; Asleh R
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac Complications in Immune Checkpoint Inhibition Therapy.
    Tajiri K; Ieda M
    Front Cardiovasc Med; 2019; 6():3. PubMed ID: 30729114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges.
    Gan L; Liu D; Ma Y; Chen X; Dai A; Zhao S; Jin X; Gu G
    Front Pharmacol; 2022; 13():962596. PubMed ID: 36110551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
    Baik AH; Tsai KK; Oh DY; Aras MA
    Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
    Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
    Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.
    Rubio-Infante N; Ramírez-Flores YA; Castillo EC; Lozano O; García-Rivas G; Torre-Amione G
    Eur J Heart Fail; 2021 Oct; 23(10):1739-1747. PubMed ID: 34196077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience.
    Xiao J; Li X; Wang X; Guan Y; Liu H; Liang J; Li Y; Wang B; Wang J
    Front Cardiovasc Med; 2023; 10():1093383. PubMed ID: 37089888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do.
    Zito C; Manganaro R; Ciappina G; Spagnolo CC; Racanelli V; Santarpia M; Silvestris N; Carerj S
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuro-ophthalmic Complications of Immune-Checkpoint Inhibitors.
    Mukharesh L; Chwalisz BK
    Semin Ophthalmol; 2021 May; 36(4):241-249. PubMed ID: 33641589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.
    Choi J; Lee SY
    Immune Netw; 2020 Feb; 20(1):e9. PubMed ID: 32158597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Zhang L; Jones-O'Connor M; Awadalla M; Zlotoff DA; Thavendiranathan P; Groarke JD; Villani AC; Lyon AR; Neilan TG
    Curr Treat Options Cardiovasc Med; 2019 Jun; 21(7):32. PubMed ID: 31175469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular toxicities associated with immune checkpoint inhibitors.
    Hu JR; Florido R; Lipson EJ; Naidoo J; Ardehali R; Tocchetti CG; Lyon AR; Padera RF; Johnson DB; Moslehi J
    Cardiovasc Res; 2019 Apr; 115(5):854-868. PubMed ID: 30715219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.